Finally, the generated anticancer putative AMPs were used in this study to inhibits Slc2a4; an important protein that responsible for energy productions during angiogenesis in tumour formation and this can serve as another novel therapeutic agent for the treatment and management of cancer. The gene discussed is SLC2A4; the disease is neoplasm.